Non-oral therapies burden PAH patients

This study looked at the challenges and impacts of non-oral treatments for pulmonary arterial hypertension (PAH), beyond those caused by PAH itself. They found that people taking oral-only therapies and people taking non-oral therapy had similar health, but those taking non-oral therapy had worse quality of life, as non-oral therapy interfered with daily activities.

Read the Therapeutic Advances in Respiratory Disease article